Adipocytes contribute to resistance of human melanoma cells to chemotherapy and targeted therapy

Current Medicinal Chemistry

Volumn 21, Issue 10, 2014, Pages 1255-1267

  Chi, M ^a,b   Chen, J ^c,d   Ye, Y ^a   Tseng, Hsin Yi ^a   Lai, F ^a   Tay, K H ^a   Jin, L ^a   Guo, S T ^b   Jiang, C C ^a   Zhang, X D ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b SHANXI CANCER HOSPITAL   (China)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Adipocyte; Leptin; MEK ERK; Melanoma; Obesity; PI3K Akt

Indexed keywords

CISPLATIN; CYCLIN D1; DOCETAXEL; INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; RECOMBINANT LEPTIN; SMALL INTERFERING RNA; VORINOSTAT;

ADIPOCYTE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROTECTION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; PROADIPOCYTE; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADIPOCYTES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CULTURE MEDIA, CONDITIONED; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; KERATINOCYTES; LEPTIN; MAP KINASE KINASE KINASES; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LEPTIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 84896303203     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131129114742     Document Type: Article

References (50)

1. Finucane, M. M.; Stevens, G. A.; Cowan, M. J.; Danaei, G.; Lin, J. K.; Paciorek, C. J.; Singh, G. M.; Gutierrez, H. R.; Lu, Y.; Bahalim, A. N.; Farzadfar, F.; Riley, L. M.; Ezzati, M. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet, 2011, 377(9765), 557-567.
2. Renehan, A. G.; Tyson, M.; Egger, M.; Heller, R. F.; Zwahlen, M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 2008, 371(9612), 569-578. (Pubitemid 351232031)
3. Calle, E. E.; Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer, 2004, 4(8), 579-591. (Pubitemid 39025053)
4. Khandekar, M. J.; Cohen, P.; Spiegelman, B. M. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer, 2011, 11(12), 886-895.
5. Chen, J.; Chi, M.; Chen, C.; Zhang, X. D. Obesity and melanoma: exploring molecular links. J. Cell. Biochem., 2013, 114(9), 1955-1961.
6. Thompson, J. F.; Scolyer, R. A.; Kefford, R. F. Cutaneous melanoma in the era of molecular profiling. Lancet, 2009, 374(9687), 362-365.
7. Platz, A.; Egyhazi, S.; Ringborg, U.; Hansson, J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol. Oncol., 2008, 1(4), 395-405.
8. Palmieri, G.; Capone, M.; Ascierto, M. L.; Gentilcore, G.; Stroncek, D. F.; Casula, M.; Sini, M. C.; Palla, M.; Mozzillo, N.; Ascierto, P. A. Main roads to melanoma. J. Transl. Med., 2009, 7, 86.
9. Bennett, D. C. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell. Melanoma Res., 2008, 21(1), 27-38. (Pubitemid 351421467)
10. Alcala, A. M.; Flaherty, K. T. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin. Cancer Res., 2012, 18(1), 33-39.
11. Luke, J. J.; Hodi, F. S. Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin. Cancer Res., 2012, 18(1), 9-14.
12. Whiteman, D. C.; Zhou, X. P.; Cummings, M. C.; Pavey, S.; Hayward, N. K.; Eng, C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int. J. Cancer, 2002, 99(1), 63-67. (Pubitemid 34273199)
13. Reifenberger, J.; Wolter, M.; Bostrom, J.; Buschges, R.; Schulte, K. W.; Megahed, M.; Ruzicka, T.; Reifenberger, G. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch., 2000, 436(5), 487-493. (Pubitemid 30312165)
14. Ye, Y.; Jin, L.; Wilmott, J. S.; Hu, W. L.; Yosufi, B.; Thorne, R. F.; Liu, T.; Rizos, H.; Yan, X. G.; Dong, L.; Tay, K. H.; Tseng, H. Y.; Guo, S. T.; de Bock, C. E.; Jiang, C. C.; Wang, C. Y.; Wu, M.; Zhang, L. J.; Hersey, P.; Scolyer, R. A.; Zhang, X. D. PI (4, 5) P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat. Commun., 2013, 4, 1508.
15. Smalley, K. S. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J. Invest. Dermatol., 2010, 130(1), 28-37.
16. Dhomen, N.; Marais, R. BRAF signaling and targeted therapies in melanoma. Hematol. Oncol. Clin. North Am., 2009, 23(3), 529-545, ix.
17. Curtin, J. A.; Fridlyand, J.; Kageshita, T.; Patel, H. N.; Busam, K. J.; Kutzner, H.; Cho, K. H.; Aiba, S.; Brocker, E. B.; Le Boit, P. E.; Pinkel, D.; Bastian, B. C. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med., 2005, 353(20), 2135-2147. (Pubitemid 41653105)
18. Van Raamsdonk, C. D.; Bezrookove, V.; Green, G.; Bauer, J.; Gaugler, L.; O'Brien, J. M.; Simpson, E. M.; Barsh, G. S.; Bastian, B. C. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature, 2009, 457(7229), 599-602.
19. Wang, P.; Mariman, E.; Renes, J.; Keijer, J. The secretory function of adipocytes in the physiology of white adipose tissue. J. Cell. Physiol., 2008, 216(1), 3-13. (Pubitemid 351813090)
20. Roberts, D. L.; Dive, C.; Renehan, A. G. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu. Rev. Med., 2010, 61, 301-316.
21. Ahima, R. S.; Osei, S. Y. Leptin signaling. Physiol. Behav., 2004, 81(2), 223-241. (Pubitemid 38670089)
22. Ahima, R. S.; Osei, S. Y. Adipokines in obesity. Front. Horm. Res., 2008, 36, 182-197.
23. Millington, G. W. Leptin, Obesity and Cutaneous Melanoma. Br. J. Dermatol., 2011, 10(1111), j1365-j2133.
24. Diwan, A. H.; Dang, S. M.; Prieto, V. G.; Ellerhorst, J. A. Lack of maturation with anti-leptin receptor antibody in melanoma but not in nevi. Mod. Pathol., 2009, 22(1), 103-106.
25. Ellerhorst, J. A.; Diwan, A. H.; Dang, S. M.; Uffort, D. G.; Johnson, M. K.; Cooke, C. P.; Grimm, E. A. Promotion of melanoma growth by the metabolic hormone leptin. Oncol. Rep., 2010, 23(4), 901-907.
26. Kushiro, K.; Chu, R. A.; Verma, A.; Nunez, N. P. Adipocytes Promote B16BL6 Melanoma Cell Invasion and the Epithelial-to-Mesenchymal Transition. Cancer Microenviron., 2012, 5(1), 73-82.
27. Kushiro, K.; Nunez, N. P. Ob/ob serum promotes a mesenchymal cell phenotype in B16BL6 melanoma cells. Clin. Exp. Metastasis, 2011, 28(8), 877-886.
28. Gillespie, S.; Zhang, X. D.; Hersey, P. Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Mol. Cancer Ther., 2005, 4(4), 668-676. (Pubitemid 40601849)
29. Wu, Z.; Xie, Y.; Morrison, R. F.; Bucher, N. L.; Farmer, S. R. PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest., 1998, 101(1), 22-32. (Pubitemid 28058899)
30. Tay, K. H.; Jin, L.; Tseng, H. Y.; Jiang, C. C.; Ye, Y.; Thorne, R. F.; Liu, T.; Guo, S. T.; Verrills, N. M.; Hersey, P.; Zhang, X. D. Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. Cell. Death Dis., 2012, 3, e337.
31. Tseng, H. Y.; Chen, L. H.; Ye, Y.; Tay, K. H.; Jiang, C. C.; Guo, S. T.; Jin, L.; Hersey, P.; Zhang, X. D. The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells. Carcinogenesis, 2012, 33(10), 1871-1881.
32. Brandon, E. L.; Gu, J. W.; Cantwell, L.; He, Z.; Wallace, G.; Hall, J. E. Obesity promotes melanoma tumor growth: role of leptin. Cancer Biol. Ther., 2009, 8(19), 1871-1879.
33. Jiang, C. C.; Mao, Z. G.; Avery-Kiejda, K. A.; Wade, M.; Hersey, P.; Zhang, X. D. Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis, 2009, 30(2), 197-204.
34. Tseng, H. Y.; Jiang, C. C.; Croft, A.; Tay, K. H.; Thorne, R. F.; Yang, F.; Liu, H.; Hersey, P.; Zhang, X. D. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol. Cancer Ther., 2010, 9(12), 3363-3374.
35. Lai, F.; Guo, S. T.; Jin, L.; Jiang, C. C.; Wang, C. Y.; Croft, A.; Chi, M. N.; Tseng, H. Y.; Farrelly, M.; Atmadibrata, B.; Norman, J.; Liu, T.; Hersey, P.; Zhang, X. D. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis., 2013, 4, e655.
36. Liang, J.; Slingerland, J. M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle, 2003, 2(4), 339-345.
37. Jiang, C. C.; Lai, F.; Tay, K. H.; Croft, A.; Rizos, H.; Becker, T. M.; Yang, F.; Liu, H.; Thorne, R. F.; Hersey, P.; Zhang, X. D. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis., 2010, 1, e69.
38. Saxena, N. K.; Vertino, P. M.; Anania, F. A.; Sharma, D. leptininduced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CY CLIN D1 promoter via activation of Stat3. J. Biol. Chem., 2007, 282(18), 13316-13325. (Pubitemid 47100545)
39. Wang, Y. F.; Jiang, C. C.; Kiejda, K. A.; Gillespie, S.; Zhang, X. D.; Hersey, P. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin. Cancer Res., 2007, 13(16), 4934-4942. (Pubitemid 47294802)
40. Piya, M. K.; McTernan, P. G.; Kumar, S. Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J. Endocrinol., 2013, 216(1), T1-T15.
41. Croft, A.; Tay, K. H.; Boyd, S. C.; Guo, S. T.; Jiang, C. C.; Lai, F.; Tseng, H. Y.; Jin, L.; Rizos, H.; Hersey, P.; Zhang, X. D. Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress. J. Invest. Dermatol., 2013. Doi: 10.1038/jid.2013.325. [Epub ahead of print].
42. Hilmi, C.; Larribere, L.; Giuliano, S.; Bille, K.; Ortonne, J. P.; Ballotti, R.; Bertolotto, C. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCLX (L), and survivin. J. Invest. Dermatol., 2008, 128(6), 1499-1505. (Pubitemid 351693181)
43. Easty, D. J.; Bennett, D. C. Protein tyrosine kinases in malignant melanoma. Melanoma Res., 2000, 10(5), 401-411.
44. Hoejberg, L.; Bastholt, L.; Schmidt, H. Interleukin-6 and melanoma. Melanoma Res., 2012, 22(5), 327-333.
45. Villanueva, J.; Herlyn, M. Melanoma and the tumor microenvironment. Curr. Oncol. Rep., 2008, 10(5), 439-446.
46. Lai, F. G., S. T.; Jiang, C. C.; Wang, C. Y.; Croft, A.; Chi, M. N.; Tseng, H. Y.; Farrelly, M.; Jin, L.; Hersey, P.; Zhang, X. D. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis., 2013, 4:e655. doi: 10.1038/cddis.2013.192.
47. Paz-Filho, G.; Lim, E. L.; Wong, M. L.; Licinio, J. Associations between adipokines and obesity-related cancer. Front. Biosci., 2011, 16, 1634-1650.
48. Ehsanipour, E. A.; Sheng, X.; Behan, J. W.; Wang, X.; Butturini, A.; Avramis, V. I.; Mittelman, S. D. Adipocytes Cause Leukemia Cell Resistance to L-Asparaginase via Release of Glutamine. Cancer Res., 2013, 73(10), 2998-3006.
49. Hersey, P.; Zhang, X. D. How melanoma cells evade trail-induced apoptosis. Nat. Rev. Cancer, 2001, 1(2), 142-150. (Pubitemid 33741889)
50. Abdulghani, J.; El-Deiry, W. S. TRAIL receptor signaling and therapeutics. Expert Opin. Ther. Targets, 2010, 14(10), 1091-1108.